荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09995 荣昌生物

休市中 04-10 16:09:20

106.000

-1.700

-1.58%

最高109.800	最低104.000	成交量450.61万
今开108.100	昨收107.700	日振幅5.39%
总市值597.42亿	流通市值221.10亿	总股本5.64亿
成交额4.77亿	换手率2.16%	流通股本2.09亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":106,"timestamp":1775808560009,"preClose":107.7,"halted":0,"volume":4506096,"delay":0,"changeRate":-0.01578458681522751,"floatShares":208581239,"shares":563608243,"eps":1.4784857693331872,"marketStatus":"休市中","change":-1.7,"latestTime":"04-10 16:09:20","open":108.1,"high":109.8,"low":104,"amount":477146282,"amplitude":0.053853,"askPrice":106,"askSize":103500,"bidPrice":105.9,"bidSize":2500,"shortable":3,"etf":0,"ttmEps":1.4784857693331872,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1776043800000},"marketStatusCode":7,"adr":0,"listingDate":1604851200000,"exchange":"SEHK","adjPreClose":107.7,"openAndCloseTimeList":[[1775784600000,1775793600000],[1775797200000,1775808000000]],"volumeRatio":0.6127597190547719,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":135.48,"timestamp":1775804400000,"preClose":137.79,"halted":0,"volume":9036200,"delay":0,"premium":"-31.73"}},"requestUrl":"/m/hq/s/09995","defaultTab":"news","newsList":[{"id":"2626192923","title":"荣昌生物：公司2025年第四季度利润增长主要系公司在第四季度确认了与Vor Biopharma Inc.就RC18达成的授权许可首付款收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2626192923","media":"证券日报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626192923?lang=zh_cn&edition=full","pubTime":"2026-04-10 19:28","pubTimestamp":1775820480,"startTime":"0","endTime":"0","summary":"证券日报网讯4月10日，荣昌生物在互动平台回答投资者提问时表示，公司2025年第四季度利润增长主要系公司在第四季度确认了与VorBiopharmaInc.就RC18达成的授权许可首付款收入，该笔收入在第四季度完成相关合同义务履行并确认。同时，核心产品泰它西普、维迪西妥单抗的销售收入亦保持良好增长态势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604103701423440.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","09995","LU1064131003.USD","688331","LU2328871848.SGD","BK0239","BK1574","LU1969619763.USD","VOR","LU2488822045.USD","LU2148510915.USD","LU1064130708.USD","BK4139","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626193856","title":"荣昌生物：维迪西妥单抗新适应症获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2626193856","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626193856?lang=zh_cn&edition=full","pubTime":"2026-04-10 16:56","pubTimestamp":1775811411,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月10日，荣昌生物(688331.SH)公告称，公司近日收到国家药监局核准签发的《药品注册证书》，维迪西妥单抗联合特瑞普利单抗用于治疗HER2表达的局部晚期或转移性尿路上皮癌的新适应症上市申请获得批准。这是维迪西妥单抗在国内获批的第五项适应症。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604103701182236.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604103701182236.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","LU1064131003.USD","LU2488822045.USD","LU1064130708.USD","LU2328871848.SGD","688331","LU2148510915.USD","BK0239","LU1969619763.USD","BK1583","BK1574","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128555891","title":"荣昌生物更新3月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1128555891","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128555891?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:36","pubTimestamp":1775723795,"startTime":"0","endTime":"0","summary":"荣昌生物制药（烟台）股份有限公司于2026年4月9日发布2026年3月股份变动月报表。报告期为2026年3月1日至2026年3月31日，公司股本结构与上月相比未发生新增发行、购回或注销股份的变动，整体保持稳定。根据公告内容，公司表示将持续按照相关法律法规及香港联交所上市规则要求进行信息披露。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625936395","title":"荣昌生物（688331）披露2025年度持续督导现场检查报告，4月7日股价下跌4.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625936395","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625936395?lang=zh_cn&edition=full","pubTime":"2026-04-07 17:07","pubTimestamp":1775552830,"startTime":"0","endTime":"0","summary":"截至2026年4月7日收盘，荣昌生物报收于141.66元，较前一交易日下跌4.99%，最新总市值为799.64亿元。近日，荣昌生物披露《华泰联合证券有限责任公司关于荣昌生物制药（烟台）股份有限公司2025年度持续督导现场检查报告》。公告显示，华泰联合证券作为保荐机构，于2026年3月31日对荣昌生物2025年度的公司治理、内部控制、信息披露、独立性、募集资金使用、关联交易、对外担保、重大对外投资及经营状况等情况进行了现场检查。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700023601.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09995","BK1161","BK0239","LU1969619763.USD","BK1583","LU2328871848.SGD","LU1064131003.USD","LU2148510915.USD","BK1574","LU1064130708.USD","LU2488822045.USD","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625957616","title":"每周股票复盘：荣昌生物（688331）双抗ADC药物获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2625957616","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625957616?lang=zh_cn&edition=full","pubTime":"2026-04-05 02:08","pubTimestamp":1775326093,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，荣昌生物报收于149.1元，较上周的123.58元上涨20.65%。本周，荣昌生物4月2日盘中最高价报150.54元，股价触及近一年最高点。本次获批不影响公司近期业绩，后续需完成临床试验并经审批方可上市。华泰联合证券作为保荐机构，于2026年3月31日完成对荣昌生物2025年度持续督导现场检查。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","LU2148510915.USD","LU2488822045.USD","BK1574","688331","LU2328871848.SGD","LU1064130708.USD","09995","LU1064131003.USD","BK0239","BK1161","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624314016","title":"中金：国产创新药产业趋势向好 26年学术领域看点较多","url":"https://stock-news.laohu8.com/highlight/detail?id=2624314016","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624314016?lang=zh_cn&edition=full","pubTime":"2026-04-03 10:41","pubTimestamp":1775184094,"startTime":"0","endTime":"0","summary":"中金主要观点如下：研发效率、临床资源优势禀赋，国产创新BD加速、量价齐升NMPA和医药魔方统计显示，2026Q1国内创新药BD总金额超600亿美元，超过2024全年、接近2025全年水平1/2；且平均首付款和平均交易规模均创历史新高。在MNC的积极推动下，多个中国创新资产有望在2026年步入上市申报阶段；基于对国内企业创新能力的认可，多个早期平台化对外合作交易陆续达成。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424995.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2399975544.HKD","06160","LU0359202008.SGD","LU2476274720.SGD","BK1588","IE00BPRC5H50.USD","01877","BK1574","LU0417516738.SGD","BK1583","BK1161","IE00B5MMRT66.SGD","LU0348784397.USD","LU0348766576.USD","LU1961090484.USD","06938","LU1770034418.SGD","09926","LU1794554557.SGD","LU0634319403.HKD","06978","01276","LU2778985437.USD","09995","LU0588546209.SGD","LU0307460666.USD","LU0348767384.USD","LU1969619763.USD","LU0359201612.USD","LU0417516571.SGD","159992","LU2328871848.SGD","LU2488822045.USD","LU0348783233.USD","BK1515","LU0348825331.USD","LU1303224171.USD","LU1720050803.USD","BK1191","LU0348735423.USD","LU1023057109.AUD","LU2543165471.USD","LU0540923850.HKD","BK1500","LU0561508036.HKD","LU1719994722.HKD","LU0348827113.USD","LU0417516902.SGD","IE00B543WZ88.USD","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624403631","title":"中金：维持荣昌生物(09995)跑赢行业评级 上调目标价至133.7港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2624403631","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624403631?lang=zh_cn&edition=full","pubTime":"2026-04-03 10:38","pubTimestamp":1775183931,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，考虑荣昌生物授权合作收入确认节奏，上调2026年净利润由0.34亿元至42.35亿元，并引入2027年净利润预测7.48亿元。考虑RC148国际化研发提速及业绩改善，基于DCF估值，该行维持跑赢行业评级，上调目标价26.8%至133.7港元，较当前股价有21.1%的上行空间。中金主要观点如下：2025年业绩超过该行预期公司公布2025年业绩：收入32.42亿元，同比增长89.55%;归母净利润7.10亿元，实现扭亏为盈。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424994.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09995","EWH","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624311466","title":"口服减重新突破，每日一粒告别针头！礼来口服GLP1药在美获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2624311466","media":"新浪基金","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624311466?lang=zh_cn&edition=full","pubTime":"2026-04-03 10:31","pubTimestamp":1775183460,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局于本周三批准了礼来公司的口服GLP-1药物Foundayo上市，标志着礼来迎来一个重要里程碑，并为进一步测试此类新型减肥药物的市场潜力提供了机会。消息公布后，礼来股价当日盘中上涨超过5%。该每日一次口服药物预计下周一起通过礼来直销平台LillyDirect开始发货，并将很快在各大药房及远程医疗平台上架销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/2026-04-03/doc-inhtetzf3810120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ELIS","LU0471298694.HKD","SG9999018857.SGD","LU2237443382.USD","LU2361044949.HKD","SG9999015978.USD","LU1712237335.SGD","LU1267930730.SGD","LU2471134796.USD","LLYX","LU2023250330.USD","09995","LU0823434740.USD","LU2264538146.SGD","LU0097036916.USD","IE00BFSS8Q28.SGD","LU0964807845.USD","LU2361044865.SGD","688331","LU1868836757.USD","LU0234572021.USD","LLII","LU0109394709.USD","LU1280957306.USD","LU1232071149.USD","LU1629891620.HKD","LU2756315318.SGD","LU0353189680.USD","IE00BK4W5L77.USD","LU0689472784.USD","LU0158827781.USD","LU2168564149.EUR","LU2237443465.HKD","BK4599","SG9999014914.USD","LU1023059063.AUD","IE00BKDWB100.SGD","LU1093756325.SGD","LU2360106947.USD","SG9999018865.SGD","LU2471134952.CNY","BK4533","LU1145028129.USD","IE00B1XK9C88.USD","LU2236285917.USD","LU2756315664.SGD","LU0640476718.USD","LU0109391861.USD","LU2213496289.HKD","LU0882574055.USD","SG9999013999.USD","BK4585","SGXZ81514606.USD","IE00BFSS7M15.SGD","LU0354030438.USD","LU2271345857.HKD","LU1069344957.HKD","IE0009355771.USD","LU2108987350.USD","LU2023251221.USD","LU0820561818.USD","LU0203201768.USD","LU0708995401.HKD","IE00BWXC8680.SGD","LU0353189763.USD","LU0203202063.USD","LU1035775433.USD","LU2106854487.HKD","IE0004445015.USD","LU1551013342.USD","IE00B4R5TH58.HKD","IE00B4JS1V06.HKD","LU0158827948.USD","IE00B7KXQ091.USD","LU0320765992.SGD","LU2462157665.USD","LU2750360641.GBP","SHWGY","LU0094547139.USD","LU0266013472.USD","LU1061106388.HKD","LU0114720955.EUR","LU2468319806.SGD","LU2552382058.USD","LU0225283273.USD","LU1291159041.SGD","SGXZ99366536.SGD","LU1093756168.USD","LU0943347566.SGD","LU1804176565.USD","LU2087625088.SGD","LU0672654240.SGD","LU2089284900.SGD","LU0471298777.SGD","SGXZ51526630.SGD","BK4007","LLY","LU2211815571.USD","IE00BFTCPJ56.SGD","SG9999001176.SGD","LU0061475181.USD","SG9999015952.SGD","LU0385154629.USD","GB00BDT5M118.USD","LU0256863902.USD","LU0820562030.AUD","LU1814569148.SGD","IE0001KFT4U8.USD","IE00B2B36J28.USD","LU0323591593.USD","LU1983299246.USD","LU1868837300.USD","LU0786609619.USD","LU1989771016.USD","LU2896262040.SGD","SG9999015986.USD","LU0238689110.USD","LU1366192091.USD","SG9999014906.USD","SG9999015945.SGD","LU1057294990.SGD","LU2237443622.USD","LU0289739699.SGD","LU2112291526.USD","LU1623119135.USD","SG9999014898.SGD","LU1064131342.USD","BK4581","IE00B1BXHZ80.USD","LU1323610961.USD","LU1868837136.USD","LU2089283258.USD","LU2357305700.SGD","SG9999014880.SGD","IE00BKPKM429.USD","LU2028103732.USD","IE00BJT1NW94.SGD","LU2552382132.HKD","LU1720051017.SGD","LU2237443895.HKD","LU2168564222.USD","LU2168564495.EUR","LU1917777945.USD","BK4588","LU0320765059.SGD","IE00BJJMRZ35.SGD","LU0456855351.SGD","LU2491050071.SGD","SG9999017495.SGD","LU1988902786.USD","LU0122379950.USD","LU2746668461.USD","LU0466842654.USD","LU0889565916.HKD","LU0417517546.SGD","LU2361045086.USD","LU2168564065.EUR","LU2461242641.AUD","LU2471134879.HKD","LU0106261372.USD","LU0432979614.USD","LU2552382215.SGD","LU2324357040.USD","LU0079474960.USD","LU2237438978.USD","LU2602419157.SGD","IE00B775H168.HKD","LU0316494557.USD","LU2237443978.SGD","LU0354030511.USD","SGXZ57979304.SGD","LU2491049909.HKD","LU0006306889.USD","LU0882574139.USD","LU1868836591.USD","LU2417539215.USD","LU0058720904.USD","IE00BJJMRX11.SGD","LU0823416689.USD","LU1974910355.USD","IE00BJLML261.HKD","LU0256863811.USD","LU0823434583.USD","LU2265009873.SGD","LU2023250504.SGD","LU2491050154.USD","IE00BK4W5M84.HKD","LU2168563687.JPY","BK4516","IE0005OL40V9.USD","LU2089984988.USD","ELIL","SGXZ31699556.SGD","IE00BN29S564.USD","IE00BJJMRY28.SGD","LU1127390331.HKD","LU1868836914.USD","LU2063271972.USD","LU0787776722.HKD","IE0004445239.USD","LU2750360997.AUD","SG9999001176.USD","IE0002141913.USD","LU1551013425.SGD","LU0683600562.USD","BK4534","LU0198837287.USD","LLYZ","LU0096364046.USD","LU2471134523.USD","LU0210536198.USD","LU0820561909.HKD","01066","LU2456880835.USD","LU1720051108.HKD","LU1548497426.USD","LU2111349929.HKD","LU2746668974.SGD","LU2237443549.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624024295","title":"荣昌生物（688331）披露双抗ADC药物RC288获临床试验批准通知书，4月2日股价上涨4.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624024295","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624024295?lang=zh_cn&edition=full","pubTime":"2026-04-02 22:02","pubTimestamp":1775138548,"startTime":"0","endTime":"0","summary":"截至2026年4月2日收盘，荣昌生物报收于149.93元，较前一交易日上涨4.12%，最新总市值为846.32亿元。荣昌生物制药（烟台）股份有限公司近日收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司自主研发的双抗ADC药物注射用RC288单药治疗局部晚期不可切除或转移性恶性实体肿瘤的I/Ⅱa期临床试验获得批准。RC288是一款同时靶向PSMA和B7H3的双特异性ADC，采用新一代偶联及毒素技术开发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040200041675.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","LU1064130708.USD","688331","BK1574","BK1161","LU1064131003.USD","LU2148510915.USD","LU2488822045.USD","LU2328871848.SGD","BK0239","LU1969619763.USD","09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624780521","title":"盈利转正、BD落地，荣昌生物全球化布局走到哪一步？","url":"https://stock-news.laohu8.com/highlight/detail?id=2624780521","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624780521?lang=zh_cn&edition=full","pubTime":"2026-04-02 11:10","pubTimestamp":1775099411,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者韩利明实习生蒋雨桐受益于核心产品商业化放量，叠加BD（商务拓展）授权收入贡献，荣昌生物（688331.SH；09995.HK）交出近三年来最优业绩答卷。2025年年报显示，期内公司实现营业收入32.51亿元，同比上涨89.36%；归母净利润扭亏为盈，达7.1亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604023693148433.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604023693148433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064131003.USD","LU1064130708.USD","LU2148510915.USD","BK1161","688331","BK1583","LU2328871848.SGD","LU2488822045.USD","09995","LU1969619763.USD","BK0239","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134735054","title":"异动解读 | 新药临床试验获批，荣昌生物盘中大涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=1134735054","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134735054?lang=zh_cn&edition=full","pubTime":"2026-04-02 10:45","pubTimestamp":1775097929,"startTime":"0","endTime":"0","summary":"荣昌生物（09995.HK）今日盘中股价大幅上涨5.07%，引起了市场的广泛关注。消息面上，公司自主研发的双特异性抗体药物偶联物（双抗ADC）注射用RC288，其单药治疗局部晚期不可切除或转移性恶性实体瘤的I/IIa期临床试验已获得国家药品监督管理局批准。这一重要的研发进展被视为公司创新管线的重要里程碑，增强了投资者对公司未来增长潜力的信心。根据公司公告，RC288是一款靶向PSMA及B7H3的双抗ADC，是公司运用新一代偶联及毒素技术研发的创新药物分子。新药临床试验的获批，标志着该药物在开发道路上迈出了关键一步，有望为相关疾病领域提供新的治疗选择。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624596896","title":"荣昌生物(688331.SH)：双抗ADC药物注射用RC288获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2624596896","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624596896?lang=zh_cn&edition=full","pubTime":"2026-04-01 16:45","pubTimestamp":1775033156,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物 发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，公司自主研发的双抗ADC药物RC288单药治疗局部晚期不可切除或转移性恶性实体肿瘤的I/Ⅱa期临床试验获得批准。RC288是一款同时靶向PSMA和B7H3的双特异性ADC，是荣昌生物采用新一代偶联及毒素技术开发的创新药物分子。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423961.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","ADC","BK0239","BK1574","LU1064130708.USD","09995","LU2328871848.SGD","BK1583","BK4080","LU2148510915.USD","LU1064131003.USD","BK4231","LU2488822045.USD","LU1969619763.USD","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624833564","title":"创新药概念股强势走高 乐普生物-B(02157)涨14.79% 机构指板块迎来多重共振","url":"https://stock-news.laohu8.com/highlight/detail?id=2624833564","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624833564?lang=zh_cn&edition=full","pubTime":"2026-04-01 13:19","pubTimestamp":1775020740,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念股强势走高，乐普生物-B 涨14.79%，荣昌生物涨14.41%，欧康维视生物-B涨14.25%，亚盛医药-B涨12.07%，博安生物涨11.41%，诺诚健华涨11.21%，海西新药涨11.19%，三生制药涨10.78%，康诺亚-B涨10.21%。华鑫证券表示，2026年中国创新出海趋势持续强化，同时市场对创新药配置有望回升，维持医药行业“推荐”的评级。创新药迎来重要配置机遇，看好目前处于领先位置的双抗和多抗组合。期待今年年4-6月重磅学术会议带来的中国创新药企重磅研究。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1978033","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","02637","02162","09969","01530","LU1969619763.USD","BK1583","02157","01477","09995","06978","06855","BK1161","LU2328871848.SGD","BK1593","BK1574","06955","HK0000165453.HKD","159992","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154880150","title":"异动解读 | 逾百家药企将亮相AACR年会，荣昌生物盘中大涨14.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154880150","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154880150?lang=zh_cn&edition=full","pubTime":"2026-04-01 12:59","pubTimestamp":1775019561,"startTime":"0","endTime":"0","summary":"荣昌生物今日盘中大涨14.41%，表现强劲。消息面上，逾百家药企将亮相美国癌症研究协会（AACR）年会，这一事件提振了整个生物医药板块的信心，恒生生物医药指数上涨6%。作为创新药企的代表之一，荣昌生物受到市场关注，股价随之大幅上扬。AACR年会是全球癌症研究领域的重要会议，药企在该会议上展示最新研究成果，往往被视为行业进展和未来潜力的风向标，从而吸引投资者买入相关股票。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623371411","title":"【券商聚焦】交银国际维持荣昌生物(09995)买入评级 指盈亏平衡可期","url":"https://stock-news.laohu8.com/highlight/detail?id=2623371411","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623371411?lang=zh_cn&edition=full","pubTime":"2026-03-31 11:04","pubTimestamp":1774926260,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，2025年，荣昌生物 产品销售收入同比+35.8%至23.07亿元，其中：1）泰它西普销售+42%至13.9 亿元，SLE仍为贡献最大的适应症，肾科和神免快速增长中、未来占比将提升；2）维迪西妥销售+22.5%至 8.8 亿元，UC 适应症贡献约70%，近期获批的乳腺癌伴肝转移有望在2026年带来较大销售贡献。此外，多项BD授权交易推动许可收入达8.95亿元。维持136港元目标价，维持买入评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977831","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","688331"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623972353","title":"3月30日荣昌生物涨5.52%，万家行业优选LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2623972353","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623972353?lang=zh_cn&edition=full","pubTime":"2026-03-30 16:26","pubTimestamp":1774859184,"startTime":"0","endTime":"0","summary":"证券之星消息，3月30日荣昌生物涨5.52%创60日新高，收盘报130.4元，换手率8.28%，成交量13.51万手，成交额17.7亿元。重仓荣昌生物的前十大公募基金请见下表：该股最近90天内共有6家机构给出评级，买入评级5家，增持评级1家；过去90天内机构目标均价为147.85。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共50家，其中持有数量最多的公募基金为万家基金的万家行业优选LOF。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000021503.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","LU1064131003.USD","BK0239","BK1583","LU1064130708.USD","LU1969619763.USD","09995","BK1161","688331","160916","LU2328871848.SGD","BK1574","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623678703","title":"部分创新药概念股逆市上扬 荣昌生物(09995)涨4.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623678703","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623678703?lang=zh_cn&edition=full","pubTime":"2026-03-30 10:23","pubTimestamp":1774837415,"startTime":"0","endTime":"0","summary":"金吾财讯 | 部分创新药概念股逆市上扬，荣昌生物 涨4.99%，康方生物涨4.75%，诺诚健华涨3.66%，先声药业涨2.73%，远大医药涨2.65%，和黄医药涨1.37%。据人民日报从国家药监局获悉，今年截至目前，我国创新药对外授权交易总额超过600亿美元，接近2025年全年的一半。今年截至3月27日，我国共批准上市10款创新药，其中8款是中国原创新药。2025年，我国批准创新药76个，创历史新高；创新药对外授权交易总金额突破1300亿美元，同样创历史新高。","market":"us","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977637","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","IE00B543WZ88.USD","09926","BK1583","LU0348735423.USD","LU2476274308.USD","06978","LU0540923850.HKD","LU0634319403.HKD","00013","LU0348784397.USD","LU2778985437.USD","LU0561508036.HKD","LU0348827113.USD","LU1794554557.SGD","LU0417516902.SGD","LU0417516738.SGD","IE00B5MMRT66.SGD","LU1969619763.USD","LU1961090484.USD","LU1064131003.USD","BK1587","LU1064130708.USD","LU2328871848.SGD","LU0348766576.USD","LU0348783233.USD","159992","09969","LU2476274720.SGD","LU2148510915.USD","BK1161","00512","688331","LU0348767384.USD","LU0348825331.USD","02096","BK1588","LU0417516571.SGD","LU1720050803.USD","LU2399975544.HKD","LU2488822045.USD","09995","BK0239","IE00BPRC5H50.USD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171506718","title":"异动解读 | 业绩扭亏为盈且收入大增近九成，荣昌生物盘中大涨10.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171506718","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171506718?lang=zh_cn&edition=full","pubTime":"2026-03-30 10:04","pubTimestamp":1774836282,"startTime":"0","endTime":"0","summary":"荣昌生物今日盘中股价大幅上涨10.04%，引起了市场的广泛关注。消息面上，公司发布了2025年度业绩报告，取得了亮眼的财务表现。报告显示，集团收益达到人民币32.42亿元，同比大幅增加89.55%；母公司拥有人应占收益为7.1亿元，成功实现扭亏为盈，去年同期为亏损14.68亿元。展望未来，新的授权首付款将陆续确认，并有潜力达成多项临床里程碑，进一步支撑收入实现跨越式增长。这些积极的业绩和前景预期共同推动了股价的强劲表现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09995"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623625553","title":"港股异动 | 荣昌生物(09995)涨超8% 全年扭亏为盈赚超7亿元 收入同比大增近九成","url":"https://stock-news.laohu8.com/highlight/detail?id=2623625553","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623625553?lang=zh_cn&edition=full","pubTime":"2026-03-30 09:53","pubTimestamp":1774835613,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荣昌生物涨超8%，截至发稿，涨8.13%，报101.8港元，成交额2.84亿港元。消息面上，荣昌生物发布2025年度业绩，该集团取得收益人民币32.42亿元，同比增加89.55%；母公司拥有人应占收益7.1亿元，去年同期则取得亏损14.68亿元。该行指，25年BD收入约9亿元，主要来自泰它西普授权首付款及认股权证；26年RC28、RC148授权首付款将陆续确认，且RC148有望达成多项临床里程碑，进一步支撑收入跨越式增长。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1421509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1064130708.USD","BK0239","BK1574","LU1969619763.USD","LU1064131003.USD","VXUS","BK1161","BK4585","688331","09995","LU2328871848.SGD","BK1583","LU2148510915.USD","LU2488822045.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623387210","title":"每周股票复盘：荣昌生物（688331）2025年净利润7.1亿元同比增148.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623387210","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623387210?lang=zh_cn&edition=full","pubTime":"2026-03-29 01:24","pubTimestamp":1774718655,"startTime":"0","endTime":"0","summary":"截至2026年3月27日收盘，荣昌生物报收于123.58元，较上周的116.73元上涨5.87%。本周，荣昌生物3月26日盘中最高价报123.89元。业绩披露要点2025年公司主营收入32.51亿元，同比上升89.36%；归母净利润7.1亿元，同比上升148.33%；扣非净利润6767.55万元，同比上升104.49%。第四季度单季主营收入15.31亿元，同比上升201.43%；单季归母净利润12.6亿元，同比上升417.52%；单季扣非净利润6.13亿元，同比上升249.4%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032900000140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09995","688331"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0799},{"period":"1month","weight":0.1713},{"period":"3month","weight":0.1199},{"period":"6month","weight":0.1355},{"period":"1year","weight":2.5452},{"period":"ytd","weight":0.4722}],"compareEarnings":[{"period":"1week","weight":0.0309},{"period":"1month","weight":-0.0002},{"period":"3month","weight":-0.0129},{"period":"6month","weight":-0.0151},{"period":"1year","weight":0.252},{"period":"ytd","weight":0.0103}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"荣昌生物制药（烟台）股份有限公司是一家主要从事生物医药研究、生物医药服务及生物医药生产和销售的中国公司。该公司专注于抗体药物偶联物（ADC）、抗体融合蛋白、单抗及双抗等治疗性抗体药物领域。该公司的主要产品包括泰它西普、维迪西妥单抗、RC28-E等。该公司的产品主要应用于自身免疫疾病、肿瘤疾病、眼科疾病等重大疾病领域。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.110172},{"month":2,"riseRate":0.666667,"avgChangeRate":0.167223},{"month":3,"riseRate":0.5,"avgChangeRate":0.012545},{"month":4,"riseRate":0.833333,"avgChangeRate":0.104663},{"month":5,"riseRate":0.4,"avgChangeRate":-0.023394},{"month":6,"riseRate":0.8,"avgChangeRate":0.127757},{"month":7,"riseRate":0.6,"avgChangeRate":-0.032319},{"month":8,"riseRate":0.4,"avgChangeRate":0.068611},{"month":9,"riseRate":0.6,"avgChangeRate":0.099222},{"month":10,"riseRate":0.4,"avgChangeRate":0.027845},{"month":11,"riseRate":1,"avgChangeRate":0.038747},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.053467}],"exchange":"SEHK","name":"荣昌生物","nameEN":"REMEGEN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,09995,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}